Back to All

Results of General Meeting

29 June, 2020

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that, further to the Company’s announcement on 11 June 2020, and in connection with the Placing of 14,371,931 new ordinary shares in the Company at a price of 145p per share (comprising a Firm Placing of 10,437,000 new ordinary shares and a Conditional Placing of 3,700,931 new ordinary shares), all resolutions put to shareholders at the general meeting held by the Company earlier today were duly passed unanimously. 10,437,000 new ordinary shares in the Company, the subject of the Firm Placing, were admitted to trading on AIM on 16 June 2020. Application has been made for the admission of 3,700,931 new ordinary shares in the Company, to trading on AIM, which is expected on 30 June 2020. For the purpose of the Disclosure and Transparency Rules, following the issue of the 3,700,931 Conditional Placing shares in connection with the Conditional Placing approved today, on 30 June 2020 the Company's issued share capital admitted to trading on AIM will comprise 84,068,923 ordinary shares of 0.2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules. Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:

ResolutionFor & DiscretionaryAgainstWithheldTotal votes cast

Number of votes%Number of votes%Number of votes
1Ordinary resolution to authorise the directors to allot shares61,914,093100.00%1,0840.00%-69,915,177
2Special resolution to authorise the directors to disapply pre-emption rights61,875,72499.94%39,4530.06%-69,915,177

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny